VP at Acadia Pharmaceuticals, pled guilty to insider trading, avoiding a $1.3M loss by illicitly selling shares ahead of a ...

Demos, a medical doctor who was the Vice President of Drug Safety and Pharmacovigilance and member of the drug label team at ...

George Demos, 64, formerly of Acadia Pharmaceuticals Inc., admitted selling more than 60,000 company shares just before news broke regarding an issue with one of the company's products ...

The former CEO of Acadia Pharmaceuticals Inc., headquartered in Sorrento Valley, pleaded guilty Friday to insider trading.

George Demos admitted selling more than 60,000 company shares just before news broke regarding an issue with one of the ...

The former vice president of a Carmel Valley pharmaceutical company pleaded guilty Friday to a federal securities fraud count ...

George Demos, 64, formerly of Acadia Pharmaceuticals Inc., admitted to insider trading for selling more than 60,000 Acadia shares just before news broke regarding an issue with one of the company ...

On Wednesday, state officials joined local leaders and private sector partners to celebrate the groundbreaking of Pacific ...

ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $26.56. The firm has a market cap of $3.32 billion, a price-to-earnings ratio of 25.58 and a beta of 0.37.

Guggenheim cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd.